Share on StockTwits

Shares of Gilead Sciences (NASDAQ:GILD) were the target of a significant decline in short interest in August. As of August 15th, there was short interest totalling 90,068,658 shares, a decline of 8.5% from the July 31st total of 98,473,543 shares, American Banking & Market News reports. Based on an average daily volume of 11,565,205 shares, the short-interest ratio is presently 7.8 days. Approximately 5.9% of the shares of the company are sold short.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 10,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $106.16, for a total transaction of $1,061,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday, August 22nd. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $105.55.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 107.56 on Tuesday. Gilead Sciences has a 1-year low of $58.81 and a 1-year high of $108.77. The stock’s 50-day moving average is $95.05 and its 200-day moving average is $83.00. The company has a market cap of $162.6 billion and a P/E ratio of 24.36.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.